Katherine Janeway, MD, MMSc
Director of Clinical Genomics, Dana-Farber Cancer Institute Senior Physician, Dana-Farber/Boston Children's Cancer and Blood Disorders Center
Associate Professor of Pediatrics, Harvard Medical School
Image
Katherine Janeway, MD, MMSc
Director of Clinical Genomics, Dana-Farber Cancer Institute Senior Physician, Dana-Farber/Boston Children's Cancer and Blood Disorders Center
Associate Professor of Pediatrics, Harvard Medical School
Medical Services
Languages
English
Education
Undergraduate School
Barnard College, Columbia University
1994
New York
NY
Medical School
Harvard Medical School
2000
Boston
MA
Internship
Medicine
Boston Children's Hospital
2001
Boston
MA
Residency
Pediatrics
Boston Combined Residency Program (BCRP)
2003
Boston
MA
Fellowship
Pediatric Hematology-Oncology
Boston Children's Hospital and Dana-Farber Cancer Institute
2007
Boston
MA
Graduate School
MMSc
Harvard Medical School
2008
Boston
MA
Publications
Preoperative Radiotherapy in Patients With Localized Ewing Sarcoma Enrolled on AEWS1031: A Report From the Children's Oncology Group. View Abstract
Incorporation of patient-reported outcomes in pediatric cancer clinical trials: design, implementation, and dissemination. View Abstract
Molecular characterization informs prognosis in patients with localized Ewing sarcoma: A report from the Children's Oncology Group. View Abstract
Rare germline structural variants increase risk for pediatric solid tumors. View Abstract
Optimizing Ewing Sarcoma and Osteosarcoma Biopsy Acquisition: A Children's Oncology Group Bone Tumor Committee Consensus Statement. View Abstract
Lenvatinib Plus Ifosfamide and Etoposide in Children and Young Adults With Relapsed Osteosarcoma: A Phase 2 Randomized Clinical Trial. View Abstract
Poverty, race, ethnicity, and survival in pediatric nonmetastatic osteosarcoma: a Children's Oncology Group report. View Abstract
Phase II Study of Samotolisib in Children and Young Adults With Tumors Harboring Phosphoinositide 3-Kinase/Mammalian Target of Rapamycin Pathway Alterations: Pediatric MATCH APEC1621D. View Abstract
Palbociclib in Solid Tumor Patients With Genomic Alterations in the cyclinD-cdk4/6-INK4a-Rb Pathway: Results From National Cancer Institute-Children's Oncology Group Pediatric Molecular Analysis for Therapy Choice Trial Arm I (APEC1621I). View Abstract
Author Correction: Molecular profiling of 888 pediatric tumors informs future precision trials and data-sharing initiatives in pediatric cancer. View Abstract
Phase II study of vemurafenib in children and young adults with tumors harboring BRAF V600 mutations: NCI-COG pediatric MATCH trial (APEC1621) Arm G. View Abstract
Overcoming Systemic Barriers to Make Patient-Partnered Research a Reality. View Abstract
Impact of age on safety of Busulfan-Melphalan followed by autologous hematopoietic stem-cell transplantation versus standard chemotherapy in the patients of the EURO-E.W.I.N.G. 99 and Ewing 2008 clinical trials. View Abstract
Molecular profiling of 888 pediatric tumors informs future precision trials and data-sharing initiatives in pediatric cancer. View Abstract
Olaparib for childhood tumors harboring defects in DNA damage repair genes: arm H of the NCI-COG Pediatric MATCH trial. View Abstract
Phase II Study of Ulixertinib in Children and Young Adults With Tumors Harboring Activating Mitogen-Activated Protein Kinase Pathway Alterations: APEC1621J of the National Cancer Institute-Children's Oncology Group Pediatric MATCH Trial. View Abstract
Autologous HER2-specific CAR T cells after lymphodepletion for advanced sarcoma: a phase 1 trial. View Abstract
Innovations in Cancer Treatment of Children. View Abstract
Tazemetostat for tumors harboring SMARCB1/SMARCA4 or EZH2 alterations: results from NCI-COG pediatric MATCH APEC1621C. View Abstract
Reply to: Comment on: A pooled subgroup analysis of glucarpidase treatment in 86 pediatric, adolescent, and young adult patients receiving high-dose methotrexate therapy in open-label trials. View Abstract
Phase 1 study of cabozantinib in combination with topotecan-cyclophosphamide for patients with relapsed Ewing sarcoma or osteosarcoma. View Abstract
Osteosarcoma Explorer: A Data Commons With Clinical, Genomic, Protein, and Tissue Imaging Data for Osteosarcoma Research. View Abstract
Long-Term Outcomes in Patients With Localized Ewing Sarcoma Treated With Interval-Compressed Chemotherapy on Children's Oncology Group Study AEWS0031. View Abstract
Evaluation of prevalence and outcomes of serial tyrosine kinase inhibitor use in pediatric patients with advanced solid tumors. View Abstract
Loss of heterozygosity does not occur in BRCA1/2 mutant pediatric solid and central nervous system tumors. View Abstract
Children's Oncology Group's 2023 blueprint for research: Bone tumors. View Abstract
A pooled subgroup analysis of glucarpidase treatment in 86 pediatric, adolescent, and young adult patients receiving high-dose methotrexate therapy in open-label trials. View Abstract
The Childhood Cancer Data Initiative: Using the Power of Data to Learn From and Improve Outcomes for Every Child and Young Adult With Pediatric Cancer. View Abstract
A single-institution pediatric and young adult interventional oncology collaborative: Novel therapeutic options for relapsed/refractory solid tumors. View Abstract
Clear cell tumor with melanocytic differentiation and MITF::CREM translocation. View Abstract
Priorities to Promote Participant Engagement in the Participant Engagement and Cancer Genome Sequencing (PE-CGS) Network. View Abstract
Genomic analysis reveals germline and somatic PDGFRB variants with clinical implications in familial infantile myofibromatosis. View Abstract
Clinical Targeted Next-Generation Panel Sequencing Reveals MYC Amplification Is a Poor Prognostic Factor in Osteosarcoma. View Abstract
Joint Adult and Pediatric Working Group as a Successful Platform to Strengthen Adolescent and Young Adult (AYA) Clinical Trial Collaboration: A Report from the NCTN/SARC AYA Clinical Trials Sarcoma Working Group. View Abstract
Randomized Phase III Trial of Ganitumab With Interval-Compressed Chemotherapy for Patients With Newly Diagnosed Metastatic Ewing Sarcoma: A Report From the Children's Oncology Group. View Abstract
Author Correction: Osteosarcoma. View Abstract
Osteosarcoma. View Abstract
Erratum to 'Linking EORTC QLQ-C-30 and PedsQL/PEDQOL physical functioning scores in patients with osteosarcoma' [Eur J Cancer 170 (2022) 209-235]. View Abstract
Rare FGFR Oncogenic Alterations in Sequenced Pediatric Solid and Brain Tumors Suggest FGFR Is a Relevant Molecular Target in Childhood Cancer. View Abstract
Analysis of Local Control Outcomes and Clinical Prognostic Factors in Localized Pelvic Ewing Sarcoma Patients Treated With Radiation Therapy: A Report From the Children's Oncology Group. View Abstract
Adverse prognostic impact of the loss of STAG2 protein expression in patients with newly diagnosed localised Ewing sarcoma: A report from the Children's Oncology Group. View Abstract
An international working group consensus report for the prioritization of molecular biomarkers for Ewing sarcoma. View Abstract
Comment on: Clinical, pathologic, and molecular features of inflammatory myofibroblastic tumors in children and adolescents: ROS1-fusion inflammatory myofibroblastic tumor: ROS1-fusion inflammatory myofibroblastic tumor. View Abstract
Paediatric Strategy Forum for medicinal product development of multi-targeted kinase inhibitors in bone sarcomas: ACCELERATE in collaboration with the European Medicines Agency with participation of the Food and Drug Administration. View Abstract
Phase 2 study of anti-disialoganglioside antibody, dinutuximab, in combination with GM-CSF in patients with recurrent osteosarcoma: A report from the Children's Oncology Group. View Abstract
Molecular profiling identifies targeted therapy opportunities in pediatric solid cancer. View Abstract
Linking EORTC QLQ-C-30 and PedsQL/PEDQOL physical functioning scores in patients with osteosarcoma. View Abstract
Gamma Secretase Inhibition for a Child With Metastatic Glomus Tumor and Activated NOTCH1. View Abstract
Histologic characterization of paediatric mesenchymal neoplasms treated with kinase-targeted therapy. View Abstract
Germline predisposition to pediatric Ewing sarcoma is characterized by inherited pathogenic variants in DNA damage repair genes. View Abstract
68 Ga-DOTATATE PET and functional imaging in pediatric pheochromocytoma and paraganglioma. View Abstract
BRCA1-associated RING domain-1 (BARD1) loss and GBP1 expression enhance sensitivity to DNA damage in Ewing sarcoma. View Abstract
Phase II Study of Selumetinib in Children and Young Adults With Tumors Harboring Activating Mitogen-Activated Protein Kinase Pathway Genetic Alterations: Arm E of the NCI-COG Pediatric MATCH Trial. View Abstract
Actionable Tumor Alterations and Treatment Protocol Enrollment of Pediatric and Young Adult Patients With Refractory Cancers in the National Cancer Institute-Children's Oncology Group Pediatric MATCH Trial. View Abstract
Rapid and highly sensitive approach for multiplexed somatic fusion detection. View Abstract
Reply to J.-G. Wang et al. View Abstract
Germline Sequencing Improves Tumor-Only Sequencing Interpretation in a Precision Genomic Study of Patients With Pediatric Solid Tumor. View Abstract
Patterns of Translocation Testing in Patients Enrolling in a Cooperative Group Trial for Newly Diagnosed Metastatic Ewing Sarcoma. View Abstract
Molecular Characterization of Inflammatory Tumors Facilitates Initiation of Effective Therapy. View Abstract
Belzutifan, a Potent HIF2a Inhibitor, in the Pacak-Zhuang Syndrome. View Abstract
Phase III Trial Adding Vincristine-Topotecan-Cyclophosphamide to the Initial Treatment of Patients With Nonmetastatic Ewing Sarcoma: A Children's Oncology Group Report. View Abstract
Identified Enrollment Challenges of Adolescent and Young Adult Patients on the Nonchemotherapy Arm of Children's Oncology Group Study ARST1321. View Abstract
Outcome of patients with relapsed or progressive Ewing sarcoma enrolled on cooperative group phase 2 clinical trials: A report from the Children's Oncology Group. View Abstract
Pediatric Cancer Data Commons: Federating and Democratizing Data for Childhood Cancer Research. View Abstract
Assessment of BCOR Internal Tandem Duplications in Pediatric Cancers by Targeted RNA Sequencing. View Abstract
Charting a path for prioritization of novel agents for clinical trials in osteosarcoma: A report from the Children's Oncology Group New Agents for Osteosarcoma Task Force. View Abstract
Gene Fusions Create Partner and Collateral Dependencies Essential to Cancer Cell Survival. View Abstract
Retrospective evaluation of single patient investigational new drug (IND) requests in pediatric oncology. View Abstract
Matched Targeted Therapy for Pediatric Patients with Relapsed, Refractory, or High-Risk Leukemias: A Report from the LEAP Consortium. View Abstract
OncoTree: A Cancer Classification System for Precision Oncology. View Abstract
Extrapolation of pharmacokinetics and pharmacodynamics of sunitinib in children with gastrointestinal stromal tumors. View Abstract
A case of metastatic adenocarcinoma of unknown primary in a pediatric patient: Opportunities for precision medicine. View Abstract
Survey of Paediatric Oncologists and Pathologists regarding Their Views and Experiences with Variant Translocations in Ewing and Ewing-Like Sarcoma: A Report of the Children's Oncology Group. View Abstract
Derivation and validation of risk groups in patients with osteosarcoma utilizing regression tree analysis. View Abstract
Desmoid tumors of the head and neck in the pediatric population: Has anything changed? View Abstract
PD-1 and PD-L1 Expression in Osteosarcoma: Which Specimen to Evaluate? View Abstract
Clinical Pan-Cancer Assessment of Mismatch Repair Deficiency Using Tumor-Only, Targeted Next-Generation Sequencing. View Abstract
Phase I/II Study of Stereotactic Body Radiation Therapy for Pulmonary Metastases in Pediatric Patients. View Abstract
Safety and efficacy of gamma-secretase inhibitor nirogacestat (PF-03084014) in desmoid tumor: Report of four pediatric/young adult cases. View Abstract
The use of interval-compressed chemotherapy with the addition of vincristine, irinotecan, and temozolomide for pediatric patients with newly diagnosed desmoplastic small round cell tumor. View Abstract
Making the most of small samples: Optimization of tissue allocation of pediatric solid tumors for clinical and research use. View Abstract
Recurrent RET gene fusions in paediatric spindle mesenchymal neoplasms. View Abstract
DICER1-associated central nervous system sarcoma in children: comprehensive clinicopathologic and genetic analysis of a newly described rare tumor. View Abstract
Genomic and Immunologic Characterization of INI1-Deficient Pediatric Cancers. View Abstract
Pediatric Trials for Cancer Therapies With Targets Potentially Relevant to Pediatric Cancers. View Abstract
Linsitinib (OSI-906) for the Treatment of Adult and Pediatric Wild-Type Gastrointestinal Stromal Tumors, a SARC Phase II Study. View Abstract
A Novel ALK Fusion in Pediatric Medullary Thyroid Carcinoma. View Abstract
Effects of dexrazoxane on doxorubicin-related cardiotoxicity and second malignant neoplasms in children with osteosarcoma: a report from the Children's Oncology Group. View Abstract
The Pan-Cancer Landscape of Coamplification of the Tyrosine Kinases KIT, KDR, and PDGFRA. View Abstract
Phase II trial of the glycoprotein non-metastatic B-targeted antibody-drug conjugate, glembatumumab vedotin (CDX-011), in recurrent osteosarcoma AOST1521: A report from the Children's Oncology Group. View Abstract
A Distinctive Genomic and Immunohistochemical Profile for NOTCH3 and PDGFRB in Myofibroma With Diagnostic and Therapeutic Implications. View Abstract
High-Dose Chemotherapy Compared With Standard Chemotherapy and Lung Radiation in Ewing Sarcoma With Pulmonary Metastases: Results of the European Ewing Tumour Working Initiative of National Groups, 99 Trial and EWING 2008. View Abstract
Provocative questions in osteosarcoma basic and translational biology: A report from the Children's Oncology Group. View Abstract
Canine osteosarcoma genome sequencing identifies recurrent mutations in DMD and the histone methyltransferase gene SETD2. View Abstract
Canine osteosarcoma genome sequencing identifies recurrent mutations in DMD and the histone methyltransferase gene SETD2. View Abstract
Sunitinib in pediatric patients with advanced gastrointestinal stromal tumor: results from a phase I/II trial. View Abstract
Emerging novel agents for patients with advanced Ewing sarcoma: a report from the Children's Oncology Group (COG) New Agents for Ewing Sarcoma Task Force. View Abstract
Correction: Detection of circulating tumour DNA is associated with inferior outcomes in Ewing sarcoma and osteosarcoma: a report from the Children's Oncology Group. View Abstract
Ushering in the next generation of precision trials for pediatric cancer. View Abstract
Renal medullary carcinomas depend upon SMARCB1 loss and are sensitive to proteasome inhibition. View Abstract
Survival and prognosis with osteosarcoma: outcomes in more than 2000 patients in the EURAMOS-1 (European and American Osteosarcoma Study) cohort. View Abstract
Duality of purpose: Participant and parent understanding of the purpose of genomic tumor profiling research among children and young adults with solid tumors. View Abstract
A Combination CDK4/6 and IGF1R Inhibitor Strategy for Ewing Sarcoma. View Abstract
A phase II study of eribulin in recurrent or refractory osteosarcoma: A report from the Children's Oncology Group. View Abstract
Factors influencing survival after recurrence in osteosarcoma: A report from the Children's Oncology Group. View Abstract
Dose Intensification Improves the Outcome of Ewing Sarcoma. View Abstract
Detection of circulating tumour DNA is associated with inferior outcomes in Ewing sarcoma and osteosarcoma: a report from the Children's Oncology Group. View Abstract
Comparison of Epidemiology, Clinical Features, and Outcomes of Patients with Reported Ewing Sarcoma and PNET over 40 Years Justifies Current WHO Classification and Treatment Approaches. View Abstract
Rationale and Design of the Targeted Agent and Profiling Utilization Registry (TAPUR) Study. View Abstract
Detection of Somatic Structural Variants Enables Quantification and Characterization of Circulating Tumor DNA in Children With Solid Tumors. View Abstract
Precision medicine in pediatric oncology. View Abstract
Response Evaluation Criteria in Solid Tumors (RECIST) following neoadjuvant chemotherapy in osteosarcoma. View Abstract
Recurrent EML4-NTRK3 fusions in infantile fibrosarcoma and congenital mesoblastic nephroma suggest a revised testing strategy. View Abstract
Identification of Patients With Localized Ewing Sarcoma at Higher Risk for Local Failure: A Report From the Children's Oncology Group. View Abstract
Osteosarcoma enters a post genomic era with in silico opportunities: Generation of the High Dimensional Database for facilitating sarcoma biology research: A report from the Children's Oncology Group and the QuadW Foundation. View Abstract
Clinical targeted exome-based sequencing in combination with genome-wide copy number profiling: precision medicine analysis of 203 pediatric brain tumors. View Abstract
Von Hippel-Lindau and Hereditary Pheochromocytoma/Paraganglioma Syndromes: Clinical Features, Genetics, and Surveillance Recommendations in Childhood. View Abstract
Cancer Screening Recommendations for Individuals with Li-Fraumeni Syndrome. View Abstract
An imprinted non-coding genomic cluster at 14q32 defines clinically relevant molecular subtypes in osteosarcoma across multiple independent datasets. View Abstract
Clinical trial enrollment of adolescents and young adults with sarcoma. View Abstract
Target and Agent Prioritization for the Children's Oncology Group-National Cancer Institute Pediatric MATCH Trial. View Abstract
Molecular profiling in the clinic: Moving from feasibility assessment to evaluating clinical impact. View Abstract
Pediatric oncology enters an era of precision medicine. View Abstract
Genomic Profiling of a Large Set of Diverse Pediatric Cancers Identifies Known and Novel Mutations across Tumor Spectra. View Abstract
Advances in the Treatment of Pediatric Bone Sarcomas. View Abstract
Surgical Management of Wild-Type Gastrointestinal Stromal Tumors: A Report From the National Institutes of Health Pediatric and Wildtype GIST Clinic. View Abstract
Liposomal doxorubicin: Effective treatment for pediatric desmoid fibromatosis. View Abstract
Institutional implementation of clinical tumor profiling on an unselected cancer population. View Abstract
Comparison of MAPIE versus MAP in patients with a poor response to preoperative chemotherapy for newly diagnosed high-grade osteosarcoma (EURAMOS-1): an open-label, international, randomised controlled trial. View Abstract
The case for informative phase 2 trials in osteosarcoma. View Abstract
Pediatric Oncology Provider Views on Performing a Biopsy of Solid Tumors in Children with Relapsed or Refractory Disease for the Purpose of Genomic Profiling. View Abstract
Patient/parent perspectives on genomic tumor profiling of pediatric solid tumors: The Individualized Cancer Therapy (iCat) experience. View Abstract
Outcome of Patients With Recurrent Osteosarcoma Enrolled in Seven Phase II Trials Through Children's Cancer Group, Pediatric Oncology Group, and Children's Oncology Group: Learning From the Past to Move Forward. View Abstract
Emerging concepts for PI3K/mTOR inhibition as a potential treatment for osteosarcoma. View Abstract
Molecular Subtypes of KIT/PDGFRA Wild-Type Gastrointestinal Stromal Tumors: A Report From the National Institutes of Health Gastrointestinal Stromal Tumor Clinic. View Abstract
Integrated genetic and pharmacologic interrogation of rare cancers. View Abstract
Multicenter Feasibility Study of Tumor Molecular Profiling to Inform Therapeutic Decisions in Advanced Pediatric Solid Tumors: The Individualized Cancer Therapy (iCat) Study. View Abstract
Assessing the Prognostic Significance of Histologic Response in Osteosarcoma: A Comparison of Outcomes on CCG-782 and INT0133-A Report From the Children's Oncology Group Bone Tumor Committee. View Abstract
Current state of pediatric sarcoma biology and opportunities for future discovery: A report from the sarcoma translational research workshop. View Abstract
Impact of Two Measures of Micrometastatic Disease on Clinical Outcomes in Patients with Newly Diagnosed Ewing Sarcoma: A Report from the Children's Oncology Group. View Abstract
Future directions in the treatment of osteosarcoma. View Abstract
Assessment of extent of surgical resection of primary high-grade osteosarcoma by treating institutions: A report from the Children's Oncology Group. View Abstract
Characterization of a novel fusion gene EML4-NTRK3 in a case of recurrent congenital fibrosarcoma. View Abstract
Rapid Protocol Enrollment in Osteosarcoma: A Report From the Children's Oncology Group. View Abstract
Integrity of the pheochromocytoma susceptibility TMEM127 gene in patients with pediatric malignancies. View Abstract
Marketing of personalized cancer care on the web: an analysis of Internet websites. View Abstract
Complementary genomic approaches highlight the PI3K/mTOR pathway as a common vulnerability in osteosarcoma. View Abstract
A summary of the osteosarcoma banking efforts: a report from the Children's Oncology Group and the QuadW Foundation. View Abstract
Exploring the association of succinate dehydrogenase complex mutations with lymphoid malignancies. View Abstract
Toward a drug development path that targets metastatic progression in osteosarcoma. View Abstract
HER-2 expression is not prognostic in osteosarcoma; a Children's Oncology Group prospective biology study. View Abstract
Post-transcriptional dysregulation by miRNAs is implicated in the pathogenesis of gastrointestinal stromal tumor [GIST]. View Abstract
Future of clinical genomics in pediatric oncology. View Abstract
Succinate dehydrogenase mutation underlies global epigenomic divergence in gastrointestinal stromal tumor. View Abstract
MicroRNA paraffin-based studies in osteosarcoma reveal reproducible independent prognostic profiles at 14q32. View Abstract
Children's Oncology Group's 2013 blueprint for research: bone tumors. View Abstract
New strategies in sarcoma therapy: linking biology and novel agents. View Abstract
Treatment guidelines for gastrointestinal stromal tumors in children and young adults. View Abstract
Cardiac paraganglioma in an adolescent. View Abstract
Pediatric gastrointestinal stromal tumor. View Abstract
Outcome for adolescent and young adult patients with osteosarcoma: a report from the Children's Oncology Group. View Abstract
Special considerations in pediatric gastrointestinal tumors. View Abstract
Differentiation of NUT midline carcinoma by epigenomic reprogramming. View Abstract
Circulating endothelial cells and circulating endothelial precursor cells in patients with osteosarcoma. View Abstract
Defects in succinate dehydrogenase in gastrointestinal stromal tumors lacking KIT and PDGFRA mutations. View Abstract
Strong expression of IGF1R in pediatric gastrointestinal stromal tumors without IGF1R genomic amplification. View Abstract
Modeling human osteosarcoma in the mouse: From bedside to bench. View Abstract
Pediatric and wild-type gastrointestinal stromal tumor: new therapeutic approaches. View Abstract
Sequelae of osteosarcoma medical therapy: a review of rare acute toxicities and late effects. View Abstract
Sunitinib treatment in pediatric patients with advanced GIST following failure of imatinib. View Abstract
Pediatric gastrointestinal stromal tumors. View Abstract
Pediatric GIST View Abstract
Pediatric KIT wild-type and platelet-derived growth factor receptor alpha-wild-type gastrointestinal stromal tumors share KIT activation but not mechanisms of genetic progression with adult gastrointestinal stromal tumors. View Abstract
Neutropenia View Abstract
Successful treatment of pediatric metastatic gastrointestinal stromal tumor (GIST) with Sunitinib after failure of imatinib View Abstract
Sunitinib treatment of pediatric metastatic GIST after failure of imatinib. View Abstract
Fever without a source in infants and young children View Abstract
Carpal tunnel syndrome and workers' compensation among an occupational clinic population in New York State. View Abstract